Content on PharmTech.com this week ranged from fundamentals on the use of digital pathology in drug development, discussions on the use of AI in pharma, and regulatory actions impacting the industry.
News|Articles|May 2, 2004
- Pharmaceutical Technology-05-02-2004
- Volume 28
- Issue 5
May 2004
Author(s)Pharmaceutical Technology Editors
Pharmaceutical Science & Technology News
Advertisement
Articles in this issue
over 22 years ago
In The Spotlight-May 2004over 22 years ago
FDA Eyes Manufacturing Innovation to Boost Drug Developmentover 22 years ago
Prepare for Bar Codingover 22 years ago
aaiPharma Situation Underscores The Need for Due Diligenceover 22 years ago
Excipient FunctionalityAdvertisement
Related to this article
The FDA approves Lilly's once-weekly insulin efsitora for type 2 diabetes, raising Fc-fusion manufacturing, high-concentration pen, and capacity questions.
The agency issued a direct final rule that supports the use of innovative testing methods to limit the use of animals and maintain existing safety standards.
The FDA approves Inluriyo-Verzenio combo for ESR1-mutated breast cancer; EMBER-3 data double PFS, with supply chain and diagnostics implications for manufacturers.
This week, the FDA opened applications for its Expedited IND Pilot, quality experts presented at the PDA/FDA Joint Regulatory Conference, and Hovione expanded its spray drying capacity.
Novartis licenses Abogen's mRNA-encoded T-cell engager for autoimmune disease, raising scale-up questions for mRNA-lipid nanoparticle manufacturing.
Pharma manufacturing spent 90 years learning that producing correct outputs isn't the same as catching your own errors. AI has only learned the first.
Ron Scarboro, Azurity Pharmaceuticals, explains why real-world usability belongs at product definition and how post-launch feedback should guide drug formulation.
Advertisement
Advertisement